Dexcom stock plunged to a four-month low Monday after the FDA issued a warning letter tied to inspections of two facilities ...

The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and ...

DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz.

Dexcom announced today that it received a warning letter from the FDA following inspections of two company facilities.

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

While these regulatory developments did not impact its ability to produce or distribute products, they may have influenced investor sentiment. The announcement came after a quarter where DexCom ...

DexCom (NasdaqGS:DXCM) recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact ...

Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...

In a regulatory filing, DexCom (DXCM) disclosed that on March 4, the company received a warning letter from the U.S. FDA following inspections ...

PNC Financial Services Group Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% in the fourth ...